APx Acquisition Corp. I (APXI)
| Previous close | 11.49 |
| Open | 11.49 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.49 - 11.49 |
| 52-week range | 9.86 - 11.49 |
| Volume | |
| Avg. volume | 5,993 |
| Market cap | 113.867M |
| Beta (5Y monthly) | 0.01 |
| PE ratio (TTM) | 28.72 |
| EPS (TTM) | 0.40 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireAPx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform
APx Acquisition Corp. I (NASDAQ: APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subjec
PR NewswireAPX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q
APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule
- PR Newswire
APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company
APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, announced today that it has signed a non-binding letter of intent ("LOI") for a proposed business combination (the "Business Combination") with a precision medicine company that offers genomic diagnostic tests in clinical genomics, oncology, human microbiome and reproductive genomics, as well as a digital nutrition-based DNA and gut microbiome wellness service that promotes wellbeing and pr
